Everest Secures Exclusive Rights to Obinutuzumab Beta Across Key Asia-Pacific Markets

MIL62 (generic name: Obinutuzumab β Injection) has been granted clinical development and commercialization rights in the Asia-Pacific region (including Southeast Asia, India, South Korea, Australia, New Zealand, as well as Hong Kong (China), Macau (China), and Taiwan (China)) under a commercial licensing agreement announced on June 4 between Everest Medicines and Tian Guangshi. The total upfront and milestone payments under this collaboration amount to RMB 209 million.

MIL62 is an innovative third-generation CD20 antibody drug independently developed by Tian Guangshi, which received its first marketing approval in China in February 2026 for the treatment of neuromyelitis optica spectrum disorder (NMOSD). In October 2025, the New Drug Application (NDA) for MIL62 for the treatment of primary membranous nephropathy (pMN) was also granted priority review by the CDE. Additionally, MIL62 is currently being evaluated in Phase III clinical trials for indications including systemic lupus erythematosus (SLE) and follicular lymphoma (FL).

Buy Obinutuzumab beta online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.